Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oscient Pharmaceuticals Corp. (OSCI) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1119)	1/20/2006 10:35:31 AM
From: Biomaven	Read Replies (2) \| Respond to of 1154

opinion that demonstrating an acceptable risk versus benefit profile for FACTIVE in ABS was not feasible, given the FDA's view of the potential risk of rash in those patients. I don't like this, and so I sold my position this morning. Doesn't sound like the FDA has an open mind on this issue, and that means the drug will always have something of a cloud over it from the perspective of off-label use and label expansion and hence from the perspective of a partner. Personally I think the FDA is wrong here given the studies the company did on the rash. Peter